



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)  
from Capital District Health Authority/*Cancer Care Nova Scotia***

**Guidelines for the Role of Pemetrexed in Malignant  
Pleural Mesothelioma (MPM)**

**Approved Use:**

**Pemetrexed / Cisplatin:** As **combination first line treatment** in patients with histologically proven MPM not candidates for curative surgery who have an ECOG performance status of 0-1 and choose to receive systemic therapy.

- This policy recommendation represents a **new guideline document** and a restriction of pemetrexed plus cisplatin as combination first line therapy for patients with proven MPM not candidates for curative surgery.